DE60122211D1 - Genregulationstherapie mit ferritin - Google Patents
Genregulationstherapie mit ferritinInfo
- Publication number
- DE60122211D1 DE60122211D1 DE60122211T DE60122211T DE60122211D1 DE 60122211 D1 DE60122211 D1 DE 60122211D1 DE 60122211 T DE60122211 T DE 60122211T DE 60122211 T DE60122211 T DE 60122211T DE 60122211 D1 DE60122211 D1 DE 60122211D1
- Authority
- DE
- Germany
- Prior art keywords
- ferritin
- gene
- expression
- disease
- iron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000008857 Ferritin Human genes 0.000 title 1
- 238000008416 Ferritin Methods 0.000 title 1
- 108050000784 Ferritin Proteins 0.000 title 1
- HBTBNXFVJYRYGI-UHFFFAOYSA-M hexadecane-1-sulfinate Chemical compound CCCCCCCCCCCCCCCCS([O-])=O HBTBNXFVJYRYGI-UHFFFAOYSA-M 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000014509 gene expression Effects 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 101710099785 Ferritin, heavy subunit Proteins 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000007056 sickle cell anemia Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024412 Friedreich ataxia Diseases 0.000 abstract 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 abstract 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 abstract 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003855 cell nucleus Anatomy 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 230000010438 iron metabolism Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Control Of Indicators Other Than Cathode Ray Tubes (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24500300P | 2000-11-01 | 2000-11-01 | |
| US245003P | 2000-11-01 | ||
| PCT/US2001/044847 WO2002036634A2 (en) | 2000-11-01 | 2001-11-01 | Gene regulation therapy involving ferritin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60122211D1 true DE60122211D1 (de) | 2006-09-21 |
| DE60122211T2 DE60122211T2 (de) | 2007-08-30 |
Family
ID=22924943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60122211T Expired - Lifetime DE60122211T2 (de) | 2000-11-01 | 2001-11-01 | Genregulationstherapie mit ferritin |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7517669B2 (de) |
| EP (1) | EP1354032B1 (de) |
| JP (1) | JP2005512941A (de) |
| AT (1) | ATE335811T1 (de) |
| AU (2) | AU2002217964B2 (de) |
| CA (1) | CA2427629A1 (de) |
| DE (1) | DE60122211T2 (de) |
| ES (1) | ES2269506T3 (de) |
| PT (1) | PT1354032E (de) |
| WO (1) | WO2002036634A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9089521B2 (en) * | 2001-11-01 | 2015-07-28 | Robert H. Broyles | Method for regulating production of hemoglobin beta chains |
| DK1764348T3 (da) * | 2005-09-16 | 2009-09-07 | Univ Delft Tech | Fremgangsm de til fjernelse af oxo-anioner og metalkationer fra en v ske |
| US8071542B2 (en) * | 2007-01-29 | 2011-12-06 | Chyna, LLC | Use of ferritin to treat iron deficiency disorders |
| US20080194529A1 (en) * | 2007-02-12 | 2008-08-14 | Auspex Pharmaceuticals, Inc. | HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS |
| MX2010010390A (es) * | 2008-03-28 | 2011-02-22 | Chyna Llc | Uso de ferritina para tratar desordenes de deficiencia de hierro. |
| US10617770B2 (en) * | 2015-04-24 | 2020-04-14 | University Of Florida Research Foundation, Incorporated | AAV vector for treatment of Friedreich's ataxia |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582820A (en) * | 1982-12-23 | 1986-04-15 | Research Corporation | Orally administered biologically active peptides and proteins |
-
2001
- 2001-11-01 EP EP01992721A patent/EP1354032B1/de not_active Expired - Lifetime
- 2001-11-01 AU AU2002217964A patent/AU2002217964B2/en not_active Ceased
- 2001-11-01 US US10/003,669 patent/US7517669B2/en not_active Expired - Fee Related
- 2001-11-01 AU AU1796402A patent/AU1796402A/xx active Pending
- 2001-11-01 PT PT01992721T patent/PT1354032E/pt unknown
- 2001-11-01 DE DE60122211T patent/DE60122211T2/de not_active Expired - Lifetime
- 2001-11-01 WO PCT/US2001/044847 patent/WO2002036634A2/en active IP Right Grant
- 2001-11-01 JP JP2002539392A patent/JP2005512941A/ja not_active Withdrawn
- 2001-11-01 AT AT01992721T patent/ATE335811T1/de not_active IP Right Cessation
- 2001-11-01 CA CA002427629A patent/CA2427629A1/en not_active Abandoned
- 2001-11-01 ES ES01992721T patent/ES2269506T3/es not_active Expired - Lifetime
-
2004
- 2004-04-06 US US10/818,676 patent/US20040186048A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT1354032E (pt) | 2006-12-29 |
| WO2002036634A3 (en) | 2003-07-24 |
| DE60122211T2 (de) | 2007-08-30 |
| ATE335811T1 (de) | 2006-09-15 |
| US20040186048A1 (en) | 2004-09-23 |
| EP1354032B1 (de) | 2006-08-09 |
| WO2002036634A2 (en) | 2002-05-10 |
| JP2005512941A (ja) | 2005-05-12 |
| ES2269506T3 (es) | 2007-04-01 |
| CA2427629A1 (en) | 2002-05-10 |
| EP1354032A2 (de) | 2003-10-22 |
| US20020128183A1 (en) | 2002-09-12 |
| AU2002217964B2 (en) | 2005-11-03 |
| AU1796402A (en) | 2002-05-15 |
| US7517669B2 (en) | 2009-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fuqua | Treatment and outcomes of precocious puberty: an update | |
| Kuter et al. | The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. | |
| Palmer et al. | Liddle’s syndrome | |
| DE60122211D1 (de) | Genregulationstherapie mit ferritin | |
| Nieto‐Bona et al. | Orthograde transport and release of insulin‐like growth factor I from the inferior olive to the cerebellum | |
| WO2007011682A3 (en) | Methods and reagents for screening new drugs and for treating ion pump associated disorders and diseases | |
| DE3688671T2 (de) | Menschliches Interferon-beta2A ; Vektoren, die Gene enthalten, die für das genannte Interferon kodieren; Zellinien, die dieses produzieren und Verwendung des genannten Interferons als Pharmazeutikum. | |
| Ausim Azizi | ... And the olive said to the cerebellum: organization and functional significance of the olivo-cerebellar system | |
| Shimizu et al. | Histochemical demonstration of ascorbic acid in the locus coeruleus of the mammalian brain | |
| CA2116327A1 (en) | Method and compositions for cellular reprogramming | |
| HUP0003116A2 (hu) | Béta-amiloid-peptid-kötő fehérjék és az őket kódoló polinukleotidok | |
| DE60143608D1 (de) | Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene | |
| Eisenbarth et al. | Inhibition of chondromucoprotein synthesis: an extraneuronal effect of nerve growth factor. | |
| Norström et al. | Effect of suckling and parturition on axonal transport and turnover of neurohypophysial proteins of the rat | |
| Breen et al. | The development of diurnal rhythmicity in fetal suprachiasmatic neurons as demonstrated by fos immunohistochemistry | |
| Cronin et al. | Tumors producing chronic hyperprolactinemia do not alter [3H] spirerone binding and dopamine turnover in the corpus striatum of the female rat | |
| TH11411EX (th) | อีพิธีลินส์ | |
| Krumwieh et al. | Biological characterization of recombinant human erythropoietin | |
| Kim et al. | Processor Application for the Magnetic Stimulation in the Cerebellum of Rat with Ischemia and its Effect on the c-Fos | |
| McGinn et al. | Cell cycle redistribution by fluorodeoxyuridine (fdurd) as a mechanism of fluoropyrmiidine radiosensttization. Supported by an ASTRO Research Fellowship | |
| Flerov et al. | The use of HSP70 for prevention of consequences of unavoidable stress in rats | |
| Benavides et al. | Susceptibility of Human Platelets, Monocytes, and Neutrophils Bioenergetics to Acetaminophen | |
| Selden et al. | Transkaryotic implantation and the somatic cell gene therapy of diabetes | |
| Xu et al. | ELECTRO-PHYSIOLOGICAL EFFECTS OF CHANGROLIN, A NEW ANTIARRHYTHMIC DRUG, ON ISOLATED CARDIAC PREPARATIONS | |
| Gaufo et al. | Thymus graft reverses morphological deficits in dorsolateral frontal cortex of congenitally athymic nude mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |